Article
Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features.
Brain pathology (Zurich, Switzerland) - 1 May 2020
Lucas Calixto-Hope G, Villanueva-Meyer Javier E, Whipple Nicholas, Oberheim Bush Nancy Ann, Cooney Tabitha, Chang Susan, McDermott Michael, Berger Mitchel, Cham Elaine, Sun Peter P, Putnam Angelica, Zhou Hong, Bollo Robert, Cheshier Samuel, Poppe Matthew M, Fung Kar-Ming, Sung Sarah, Glenn Chad, Fan Xuemo, Bannykh Serguei, Hu Jethro, Danielpour Moise, Li Rong, Alva Elizabeth, Johnston James, Van Ziffle Jessica, Onodera Courtney, Devine Patrick, Grenert James P, Lee Julieann C, Pekmezci Melike, Tihan Tarik, Bollen Andrew W, Perry Arie, Solomon David A
Abstract excerpt
"Myxoid glioneuronal tumor, PDGFRA p.K385-mutant" is a recently described tumor entity of the central nervous system with a predilection for origin in the septum pellucidum and a defining dinucleotide mutation at codon 385 of the PDGFRA oncogene replacing lysine with either leucine or isoleucine (p.K385L/I). Clinical outcomes and optimal treatment for this new tumor entity have yet to be defined. Here, we report...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.